Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status

Jin, Yoon; Kim, Hye Ryun; Lee, Chang Young; Cho, Byoung Chul; Shim, Hyo Sup

doi:10.1016/j.lungcan.2016.05.001

Cited by 135 publications

(122 citation statements)

References 34 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…), which could influence PD-L1 expression and the composition of the tumor microenvironment. 45,46 However, our other control group of EGFR-mutated lung tumors was well defined and homogeneous and ALK-positive lung cancer patients clearly displayed a higher frequency of predictive biomarkers of clinical response than this control group.…”

Section: Cd8mentioning

confidence: 63%

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy

et al. 2017

View full text Add to dashboard Cite

Anaplastic lymphoma kinase (ALK) inhibitors have been successfully developed for non-small cell lung carcinoma (NSCLC) displaying chromosomal rearrangements of the ALK gene, but unfortunately resistance invariably occurs. Blockade of the PD-1-PD-L1/2 inhibitory pathway constitutes a breakthrough for the treatment of NSCLC. CD8C T cells was also observed in ALK-positive lung cancer patients compared with EGFR-mutated (p D 0.03) or WT patients (p D 0.012). These results strongly suggest that a subgroup of ALK-positive lung cancer patients may constitute good candidates for anti-PD-1/-PD-L1 therapies.

show abstract

Section: Cd8mentioning

confidence: 63%

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Poor, recurrence-free, and overall survival in patients with high PD-L1 expression assessed with univariate analysis were reported (both p < 0.001), exact median PFS and overall survival (OS) were not reported in numbers (e.g., months). Authors conclude that high PD-L1 expression is associated with poor prognosis of patients [19].…”

Section: Pd-l1 As a Prognostic And Predictive Biomarkermentioning

confidence: 94%

“…Poor responses and high expression of PD-L1 have been found in several cancers including melanoma, breast, bladder, ovary, pancreas, kidney, esophagus, and hematologic malignancies [1,18,19]. Results are not constant; some authors report no correlation or even improved survival of patients with tumors highly expressing PD-L1 [18,20].…”

Section: Pd-l1 As a Prognostic And Predictive Biomarkermentioning

confidence: 99%

“…Many authors suggest that high expression is connected to better prognosis, while others found just the opposite [19]. Cha Higher expression (over 50%) was more prevalent in former or current smokers compared to nonsmokers (p = 0.026) and was associated with more pack-years of smoking (p = 0.016) [19]. Survival analysis was performed on 316 patients who underwent complete surgical resection (Stages I-IIIA disease).…”

Section: Pd-l1 As a Prognostic And Predictive Biomarkermentioning

confidence: 99%

“…PD-L1 expression is a dynamic rather than static process that varies according to different tumor and host factors (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30). Several data show that anti-PD-L1 drugs are more effective in patients whose tumors express PD-L1, but responses in the population of patients without the expression lead to the conclusion that these patients also benefit from this treatment.…”

Section: The Problems Of Pd-l1 As a Biomarkermentioning

confidence: 99%

See 2 more Smart Citations

Prognostic and Predictive Value of PD-L1 in Patients with Lung Cancer

Rajer¹

2017

A Global Scientific Vision - Prevention, Diagnosis, and Treatment of Lung Cancer

View full text Add to dashboard Cite

Improved understanding of the molecular mechanisms has led to identification of checkpoint signalling and development of checkpoint inhibitors in the treatment of many cancers, including lung cancer. To be able to select the patients who benefit most from checkpoint inhibitors, predictive biomarkers are needed. Currently, the only predictive biomarker that has been approved in clinical use is PD-L1, the ligand of the inhibitory T-cell checkpoint PD-1. The use of PD-L1 as a predictive biomarker is confounded by multiple unresolved issues, from testing issues (e.g., cut-off values for positivity) to clinical use (e.g., the response to anti-PD-1 and anti-PD-L1 antibodies in patients without any expression of PD-L1). Even more open questions exist in the evaluation of PD-L1 as a prognostic biomarker. In the future, we expect that an improved understanding of immune system, tumor microenvironment, mechanism of action of immunotherapeutic drugs, and PD-L1 testing methods will elucidate the value of PD-L1 as a prognostic and predictive biomarker in detail.

show abstract

PD‐L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer

Sui

Song

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status

Cited by 135 publications

References 34 publications

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy

Prognostic and Predictive Value of PD-L1 in Patients with Lung Cancer

PD‐L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer

Contact Info

Product

Resources

About